Only C/L and VAMD therapies significantly decreased mean serum α‐synuclein levels and increased serum ApoA1 levels compared to the untreated rats with induced PD (PC group) (p ≤ 0.001). The gene discussed is APOA1; the disease is Parkinson disease.